Podcasts about Peripheral neuropathy

What's the problem with antibiotics anyway? On this episode of Vitality Radio, Jared passionately answers this question. There is no antibiotic that doesn't cause harm. That's not to say they don't have their place, but as Jared explains, they are almost never necessary and almost always prescribed for common problems like UTI's and sinus infections. You'll learn why many infections don't need, and won't respond to antibiotics, the ramifications of even a single dose of antibiotics, and how antibiotic superbugs are a real problem. Jared delves into why antibiotics are overused, side effects of particularly dangerous forms, and the effects on mental health and the immune system. This show will be followed with one on antibiotic alternatives and ways to rebuild your microbiome after antibiotic exposure.Additional Information:#264: Emotional Vitality: Jen's Story Part 1 - From Addiction and Mental Illness to Vitality#266: Prescribing Poisons Part 2. Ibuprofen, PPI's, and Flouroquinalone AntibioticsVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

In this podcast episode, Dr. Michael Chu discusses the management of peripheral neuropathy associated with the use of brentuximab vedotin for the first-line treatment of classical Hodgkin Lymphoma. Our GuestDr. Michael Chu is a clinician scientist at the Cross Cancer Institute and an Associate Professor at the University of Alberta in Edmonton, Alberta.This podcast episode was sponsored by Pfizer Canada Inc.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

The March 2025 replay features four previously released episodes focused on peripheral neuropathy and radiculopathy. The episode begins with Dr. Anne Oaklander discussing the association between long COVID and the development of polyneuropathy affecting small-fiber axons. This is followed by another interview with Dr. Oaklander, where she shares key takeaways for clinicians regarding the management of small-fiber neuropathy. The third segment features Drs. Raymond Price and Brian Callaghan discussing practice guidelines for painful diabetic neuropathy. The episode concludes with Dr. Carmel Armon addressing the efficacy of epidural steroid injections in treating cervical and lumbar spinal stenosis and radiculopathies. Podcast Links: Peripheral Neuropathy and Prolonged COVID  Relapsing-Remitting Immunotherapy Responsive SFN  Practice Guidelines for Painful Diabetic Neuropathy Epidural Steroids for Cervical and Lumbar Radicular Pain and Spinal Stenosis Article Links:  Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID  Relapsing-Remitting Immunotherapy Responsive Small-Fiber Neuropathy  Epidural Steroids for Cervical and Lumbar Radicular Pain and Spinal Stenosis Systematic Review Summary  Disclosures can be found at Neurology.org.

In this "Giants in Plastic Surgery" episode of the PRS Global Open Deep Cuts Podcast, A. Lee Dellon discusses his journey through plastic surgery, from his early training at Johns Hopkins to his groundbreaking PhD research on nerve compression. Dr. Dellon discusses how his work in nerve regeneration, particularly in diabetic neuropathy, has shaped modern treatments for chronic pain. Dr. Dellon reflects on the mentors who inspired him, the challenges he's overcome, and his thoughts on the future of nerve compression treatment. This conversation is a deep dive into a career driven by innovation, compassion, and a relentless pursuit of healing. Read a classic PRS Global Open article by Dr. Dellon and co-authors, “Treatment of Peripheral Neuropathy in Leprosy: The Case for Nerve Decompression”: https://bit.ly/NDinLeprosy   Dr. A. Lee Dellon is a renowned plastic and reconstructive surgeon with an exceptional academic and clinical background. A graduate of Johns Hopkins University and its School of Medicine, Dr. Dellon completed extensive training, including a plastic surgery residency at Johns Hopkins Hospital and a hand surgery fellowship at the Raymond M. Curtis Hand Center. He is currently a Professor of Plastic Surgery and Neurosurgery at Johns Hopkins University and has received a PhD from the University of Utrecht for his groundbreaking research in nerve compression and diabetic neuropathy. Dr. Dellon is board-certified in plastic surgery and holds the Certificate of Added Qualifications in Hand Surgery. With a research focus on neural regeneration, Dr. Dellon has made significant contributions to the treatment of nerve-related conditions, such as peripheral neuropathy, facial pain, and pelvic pain from pudendal nerve problems. He has received 23 national research awards, authored over 450 peer-reviewed articles, and written seven books, including his latest, Pain Solutions. A founding member of the American Society for Peripheral Nerve and past president of the American Society of Reconstructive Microsurgery, Dr. Dellon also directs the Dellon Institutes for Peripheral Nerve Surgery in Baltimore and Henderson, Nevada. His work continues to advance the field of nerve surgery and improve the lives of patients suffering from chronic pain. Your host, Dr. Vimal Gokani, is a senior Specialty Registrar in plastic surgery in London, England. Your producer & editor, Charlene Kok, is a Year 3 Medical Student in Imperial College London, England, with a keen interest in Plastic Surgery. #PRSGlobalOpen #DeepCutsPodcast #PlasticSurgery #GiantsPlasticSurgery

Dr. Tom Roselle DC discusses how to heal and reprogram a dysregulated nervous system for maximum function and capacity. For all episodes of Ageless Health with Dr. Tom Roselle, DC, visit https://www.drtomroselle.com #agelesshealth #podcast @wmaldc #nervoussystem #neuropathy #peripheralneuropathy #proximalneuropathy #focalneuropathy #autonomicneuropathy #chronicpain #paresthesia #muscleweakness #numbness #cirrhosis #diabetes #hypothyroidism #shingles #vitaminDdeficiency #lymedisease #kidneydisease #autoimmunedisease #erectiledysfunction #spinalstenosis #carpeltunnelsyndrome #nerveinjury #facialparalysis

Dr. Tom Roselle DC discusses the major warning signs in affected nerves of diabetic neuropathy including symptoms like pain and numbness in legs, hands, and feet. Also to be addressed problems in the digestive system, urinary tract, blood vessels, and heart. For all episodes of Ageless Health® with Dr. Tom Roselle, DC, visit https://www.drtomroselle.com #agelesshealth #podcast @wmaldc #neuropathy #peripheralneuropathy #proximalneuropathy #focalneuropathy #autonomicneuropathy #chronicpain #paresthesia #muscleweakness #numbness #cirrhosis #diabetes # hypothyroidism #shingles #vitaminDdeficiency #lymedisease #kidneydisease #autoimmunedisease #erectiledysfunction #spinalstenosis #carpeltunnelsyndrome #nerveinjury #facialparalysis

Dr. Tom Roselle DC discusses neuropathy types and distinguishes the causes and effects of peripheral, proximal, focal, and autonomic neuropathy. For all episodes of Ageless Health® with Dr. Tom Roselle, DC, visit https://www.drtomroselle.com #agelesshealth #podcast @wmaldc #neuropathy #peripheralneuropathy #proximalneuropathy #focalneuropathy #autonomicneuropathy #chronicpain #paresthesia #muscleweakness #numbness #cirrhosis #diabetes # hypothyroidism #shingles #vitaminDdeficiency #lymedisease #kidneydisease #autoimmunedisease #erectiledysfunction #spinalstenosis #carpeltunnelsyndrome #nerveinjury #facialparalysis

Dr. Prather has a high success rate in treating Peripheral Neuropathy, which he says is "unusual".  In this episode, find out:—How Diabetes is the most common reason for Peripheral Neuropathy, where a Diabetic has a 50% chance of having Neuropathy.  And how it is "rare" to go through Chemotherapy without experiencing Neuropathy as a side-effect.—The connection between Neuropathy and Free Radical Pathology.  And how getting Free Radicals under control is also a key to slowing down the aging process and preventing diseases such as Cardiovascular Disease and Cancer.—Why Dr. Prather says he believes one of the reasons for his success in treating Peripheral Neuropathy is because his office addresses the viruses (like the  Coxsackie B virus) affecting the nervous system. —How prescription drugs, especially Statin drugs, can be a major contributor to Neuropathy.  And how even some of the nerve drugs prescribed for Neuropathy can actually CAUSE Neuropathy. —The Diathermy treatment that Dr. Prather says is "like a magic formula" for Neuropathy and a key reason for his success rate in treating the condition.—The stories of how Dr. Prather has helped many Neuropathy patients to avoid amputations.—How the Chinese liniments used at Holistic Integration can often provide immediate pain relief for Neuropathy.  And the reason Dr. Prather does not use the Capsacin liniments more commonly used for Neuropathy.—Why Chiropractic and Acupuncture are helpful for treating Neuropathy.  And the lifestyle changes recommended for Neuropathy patients, including smoking cessation, exercise, and proper nutritional support through diet.—The necessary diagnostics for Neuropathy.  And how Dr. Prather is able to even detect Neuropathy early before the patients are even complaining about their symptoms.—Plus, we reveal the details about how you can be a part of our FREE Holistic Heart Open House event with Dr. Prather on Wednesday, October 23, 2024 at 6 p.m.http://www.TheVoiceOfHealthRadio.com

Join Dr. Jay and Brad as they interview their friend, Dr. Dan Ruitenbeek! Dr. Dan grew up in London, Ontario Canada. He is on a mission to make sure that the community thrives in life, rather than suffers. After an ice hockey injury of multiple lumbar vertebral disk protrusions rendered him unable to walk or sit without pain, let alone play any kind of sports, Dr. Dan was referred to his hometown natural health clinic. Through chiropractic care and physical rehabilitation this doctors office was able to actually assess the underlying weaknesses that led to the injury and provide long lasting results. Fascinated by this approach to wellness, Dr. Dan became obsessed with the idea of a collaborative, integrated health model. People deserve to have easy access to the best of both worlds; modern medical interventions and natural/preventative healthcare working together to provide high quality, customized solutions. Dr. Dan has his bachelors degree in Kinesiology, Doctorate in Chiropractic, Board certification in Intractable Pain and Neuropathy as well as various soft tissue therapy certifications. Dr. Dan is also the author of “Cracking the Neuropathy Code: A state-of-the-art approach to reversing peripheral neuropathy” He has incredible success rates in reversing the effects of Peripheral Neuropathy through an integrative, holistic approach to rebuild nerve tissue and re-establish proper blood flow. This approach has been highly beneficial for a variety of other chronic health issues including Sciatica, Fibromyalgia, Nerve damage, Plantar Fasciitis, and Degenerative Arthritis. Dr. Dan loves spending his time in athletics, and spending as much time as possible with his wife Ally. He is very excited to be serving the Atlanta area with truly customized, objective and specific integrated healthcare that is safe and effective for the whole family. To connect with Dr. Dan, visit his website at https://www.shockwavecenters.com/ or email him at DrDan@ShockwaveCenters.com

Matthew Schultz, Ph.D., and Amy White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.(00:31) Would you share a little bit about yourself and your background? (01:11) Could you provide us with an overview of this particular peripheral neuropathy?  (03:09) Can you share the background as to how your team learned about this condition and how you considered testing for it? (04:42)Would you explain what you saw when you performed the urine test on the first patient? (05:26) Were you able to test additional patients with this condition? (06:09)Could you expand on why this urine test is important? (07:20) How does a health care provider order urine testing for SORD deficiency? (07:59) How does this new SORD urine test complement the existing Mayo Clinic Laboratories test menu? (08:55)Could you summarize the benefits of ordering this SORD urine test at Mayo?

Peripheral neuropathy can pose various dangers depending on its severity and the specific nerves affected. Some of the primary concerns include:1. **Loss of Sensation**: This is one of the most common symptoms of peripheral neuropathy. Reduced sensation, especially in the feet and hands, can lead to an increased risk of injuries like burns, cuts, or ulcers, as individuals may not feel pain or temperature changes.2. **Balance and Mobility Issues**: Muscle weakness or numbness can affect coordination and balance, making falls more likely. This can be particularly dangerous for older adults, increasing the risk of fractures or serious injuries.3. **Chronic Pain**: Neuropathy can lead to ongoing pain, including burning, tingling, or stabbing sensations, which can significantly impact a person's quality of life and mental health.4. **Infections**: Due to numbness, individuals may not notice wounds, especially on the feet. Untreated wounds can become infected, and in severe cases, lead to gangrene or amputation, particularly for people with diabetes.5. **Autonomic Dysfunction**: If the autonomic nerves are affected, this can lead to abnormal heart rate, blood pressure fluctuations, digestive problems, or even bladder control issues. 6. **Muscle Weakness and Atrophy**: Damage to motor nerves can cause muscle weakness, difficulty with fine motor skills, or even muscle atrophy over time, impacting mobility and daily functioning.Proper diagnosis and management of peripheral neuropathy are essential to mitigate these risks. Neuropathy@CoreHealth is Fairfield County's Leading Provider of Neuropathic Relief 203-875-0846This podcast welcomes your feedback here are several ways to reach out to me. If you have a topic you would like to hear about send me a message. I appreciate your listening. Dr. Brian Mc Kayhttps://twitter.com/DarienChiro/https://www.facebook.com/ChiropractorBrianMckayhttps://chiropractor-darien-dr-brian-mckay.business.sitehttps://podcasts.apple.com/us/podcast/not-just-chiropractor-for-stamford-darien-norwalk-new/id1503674397?uo=4Core Health Darien-Dr.Brian Mc Kay 551 Post RoadDarien CT 06820203-656-363641.0833695 -73.46652073GMP+87 Darien, Connecticuthttps://youtu.be/WpA__dDF0O041.0834196 -73.46423349999999https://darienchiropractor.comhttps://darienchiropractor.com/darien/darien-ct-understanding-pain/Find us on Social Mediahttps://chiropractor-darien-dr-brian-mckay.business.site https://www.youtube.com/channel/UCNHc0Hn85Iiet56oGUpX8rwhttps://docs.google.com/spreadsheets/d/1nJ9wlvg2Tne8257paDkkIBEyIz-oZZYy/edit#gid=517721981https://goo.gl/maps/js6hGWvcwHKBGCZ88https://www.youtube.com/my_videos?o=Uhttps://www.linkedin.com/in/darienchiropractorhttps://www.facebook.com/ChiropractorBrianMckayhttps://sites.google.com/view/corehealthdarien/https://sites.google.com/view/corehealthdarien/home

Trust in doctors craters in wake of Covid; Mother, don't let your children grow up to be doctors; Does a diagnosis of hiatal hernia require lifelong acid-blockers? If you're reluctant to get a colonoscopy, stool tests and a newly-approved blood test may suffice for prevention; When drugs aren't tolerated, are there natural alternatives for peripheral neuropathy pain? Supplements for insomnia can help—but a comprehensive lifestyle approach is necessary to optimize sleep; The movement to kick Big Soda sponsors out of sport; NFL Kelce brothers sell out to endorse sugary cereal; North Korea's Kim Jong Un is a heart attack waiting to happen.

ttps://.neuropathyct.com Peripheral neuropathy, a condition resulting from damage to the peripheral nerves, often leads to chronic pain, tingling, and numbness. To manage these symptoms, medications such as Gabapentin (Neurontin), Pregabalin (Lyrica), and Duloxetine (Cymbalta) are frequently prescribed. While these drugs can offer significant relief, their use comes with a range of potential dangers and side effects that patients and healthcare providers must carefully consider. DizzinessFatigueDrowsinessLoss of coordinationPeripheral edema (swelling of extremities)NauseaVomitingBlurred visionTremorsWeight gainLess common but more serious side effects include:Mood changes (such as depression or anxiety)Suicidal thoughtsDifficulty breathingSevere allergic reactions (rash, itching, swelling, severe dizziness, trouble breathing)Severe muscle pain or weaknessGabapentin can also interact with other medications, so it's important to inform your healthcare provider of all drugs and supplements you are taking. Additionally, stopping gabapentin suddenly can lead to withdrawal symptoms, so it should be tapered off gradually under a doctor's supervision. Always consult with your healthcare provider for personalized advice and informationNeuropathy@CoreHealth551 Post RoadDarien CT 06820203-875-0846.This podcast welcomes your feedback here are several ways to reach out to me. If you have a topic you would like to hear about send me a message. I appreciate your listening. Dr. Brian Mc Kayhttps://twitter.com/DarienChiro/https://www.facebook.com/ChiropractorBrianMckayhttps://chiropractor-darien-dr-brian-mckay.business.sitehttps://podcasts.apple.com/us/podcast/not-just-chiropractor-for-stamford-darien-norwalk-new/id1503674397?uo=4Core Health Darien-Dr.Brian Mc Kay 551 Post RoadDarien CT 06820203-656-363641.0833695 -73.46652073GMP+87 Darien, Connecticuthttps://youtu.be/WpA__dDF0O041.0834196 -73.46423349999999https://darienchiropractor.comhttps://darienchiropractor.com/darien/darien-ct-understanding-pain/Find us on Social Mediahttps://chiropractor-darien-dr-brian-mckay.business.site https://www.youtube.com/channel/UCNHc0Hn85Iiet56oGUpX8rwhttps://docs.google.com/spreadsheets/d/1nJ9wlvg2Tne8257paDkkIBEyIz-oZZYy/edit#gid=517721981https://goo.gl/maps/js6hGWvcwHKBGCZ88https://www.youtube.com/my_videos?o=Uhttps://www.linkedin.com/in/darienchiropractorhttps://www.facebook.com/ChiropractorBrianMckayhttps://sites.google.com/view/corehealthdarien/https://sites.google.com/view/corehealthdarien/home

In this episode we have Rebound Rehab physical therapy in house. We discuss Ozzie Albies, Max Fried, listener questions about plantar fibromas, peripheral neuropathy and more. 

Visit learnAMAstyle.com to uplevel your writing and editing skills with free downloads on medical writing and editing. The FDA has approved vonoprazan (Voquenza) for treating non-erosive gastroesophageal reflux disease (GERD) in adults. Vonoprazan is an oral potassium-competitive acid blocker (PCAB) already approved for erosive esophagitis and Helicobacter pylori infection. PCABs are a new class of medicines that inhibit stomach acid secretion. Non-erosive GERD is the most common form of GERD, affecting around 45 million US adults, with about 15 million treated with prescription medication annually. Many patients remain dissatisfied with existing treatments, experiencing symptoms that affect their quality of life. The approval of vonoprazan was based on the Phalcon-Nerd-301 study, a Phase 3 trial showing it significantly reduced heartburn episodes and provided more heartburn-free days and nights compared to placebo. The trial included 772 adults with frequent heartburn, demonstrating vonoprazan's effectiveness over placebo. The FDA has granted fast track designation to ADI-270 for metastatic or advanced clear cell renal cell carcinoma (ccRCC) in patients who previously received an immune checkpoint inhibitor and a VEGF inhibitor. ADI-270 is a CD70-targeted gamma delta CAR T-cell therapy designed to enhance resilience to the tumor microenvironment. A phase 1/2 trial will evaluate ADI-270 in patients with confirmed ccRCC who have been previously treated. The primary endpoints are the incidence of dose-limiting toxicities and the proportion of treatment-emergent adverse effects. The FDA has granted Fast Track and Regenerative Medicine Advanced Therapeutic (RMAT) designations to Lomecel-B, an investigational MSC therapy for Alzheimer's disease (AD). Lomecel-B aims to address neurodegeneration in AD and showed positive results in the CLEAR MIND Phase 2a trial. Visit learnAMAstyle.com to uplevel your writing and editing skills with free downloads on medical writing and editing.

Https://neuropathyct.comCommon Symptoms and SignsExperiencing diabetic peripheral neuropathy may manifest in various common symptoms and signs that signal nerve damage in your body. When diabetes causes nerve damage, you might feel numbness, tingling, or burning sensations in your hands, feet, legs, or arms.This diabetic nerve damage can also lead to a reduced ability to feel pain, changes in temperature, or touch sensitivity. Sharp or shooting pains in these areas, along with muscle weakness, coordination difficulties, and foot deformities like hammertoes, are also signs of diabetes and nerve pain.Additionally, you may notice sensitivity to touch or pressure and experience challenges with balance and walking. Recognizing these symptoms early on is crucial for prompt management and treatment of diabetic peripheral neuropathy.If you're experiencing any of these signs, seeking medical advice from a healthcare professional like Dr. McKay is essential for proper diagnosis and personalized care.Dr.brianThis podcast welcomes your feedback here are several ways to reach out to me. If you have a topic you would like to hear about send me a message. I appreciate your listening. Dr. Brian Mc Kayhttps://twitter.com/DarienChiro/https://www.facebook.com/ChiropractorBrianMckayhttps://chiropractor-darien-dr-brian-mckay.business.sitehttps://podcasts.apple.com/us/podcast/not-just-chiropractor-for-stamford-darien-norwalk-new/id1503674397?uo=4Core Health Darien-Dr.Brian Mc Kay 551 Post RoadDarien CT 06820203-656-363641.0833695 -73.46652073GMP+87 Darien, Connecticuthttps://youtu.be/WpA__dDF0O041.0834196 -73.46423349999999https://darienchiropractor.comhttps://darienchiropractor.com/darien/darien-ct-understanding-pain/Find us on Social Mediahttps://chiropractor-darien-dr-brian-mckay.business.site https://www.youtube.com/channel/UCNHc0Hn85Iiet56oGUpX8rwhttps://docs.google.com/spreadsheets/d/1nJ9wlvg2Tne8257paDkkIBEyIz-oZZYy/edit#gid=517721981https://goo.gl/maps/js6hGWvcwHKBGCZ88https://www.youtube.com/my_videos?o=Uhttps://www.linkedin.com/in/darienchiropractorhttps://www.facebook.com/ChiropractorBrianMckayhttps://sites.google.com/view/corehealthdarien/https://sites.google.com/view/corehealthdarien/home

This episode is about the six webinar series being put on this summer by the Foundation for Peripheral Neuropathy.

This episode is sponsored by Medtronic.Painful diabetic peripheral neuropathy (DPN) can significantly impact a person with diabetes and their quality of life. Nalani Hunsaker PA-C, MCMSc, BC-ADM, a paid consultant for Medtronic, joins The Huddle to talk about Medtronic's spinal cord stimulation therapy option, how the procedure works, and its success in relieving pain from DPN. Please reach out to http://www.medtronic.com/dpnconnect to connect with a Medtronic representative today. If you would like to share more information with your patients check out http://www.medtronic.com/dpnpain References:1. de Vos CC, Meier K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: A multicentre randomized clinical trial. Pain. 2014;155(11):2426–2431. doi:10.1016/j.pain.2014.08.031 2. Slangen R, Schaper NC, Faber CG, et al. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: A prospective two-center randomized controlled trial. Diabetes Care. 2014;37(11):3016–3024. doi:10.2337/dc14-0684 3. Medtronic Pain Therapy Clinical Summary M221494A016 Rev B. United States; 2022. 4. van Beek M, Geurts JW, Slangen R, et al. Severity of neuropathy is associated with long-term spinal cord stimulation outcome in painful diabetic peripheral neuropathy: Five-year follow-up of a prospective two-center clinical trial. Diabetes Care. 2018;41(1):32–38. doi:10.2337/dc17-0983 5. Zuidema X et al. Long-term Evaluation of Spinal Cord Stimulation in Patients With Painful Diabetic Polyneuropathy: An Eight-to-Ten-Year Prospective Cohort Study. Neuromodulation. 2022 Dec 30:S1094-7159(22)01403-9. 6. Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. N Engl J Med. 2019;380(20):1895-19057. Desai MJ, Hargens LM, Breitenfeldt MD, Doth AH, Ryan MP, Gunnarsson C, Safriel Y. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine (Phila Pa 1976). 2015 1;40(9):E531-7.8. Mullins CF, Harris S, Pang D. A retrospective review of elevated lead impedances in impedance-dependent magnetic resonance-conditional spinal cord stimulation devices. Pain Pract. 2023;00:1–8 https://creativecommons.org/licenses/by/4.0/.9. Temel Y, Ackermans L, Celik H, et al. Management of hardware infections following deep brain stimulation. Acta Neurochir (Wien). April 2004;146(4):355-361.10. Pepper J. Zrinzo L, Mirza B, Foltynie T, Limousin P, Hariz M. The risk of hardware infection in deep brain stimulation surgery is greater at impulse generator replacement than at the primary procedure. Stereotact Funct Neurosurg. 2013;91(1):56-65.11. Tolleson C, Stroh J, Ehrenfeld J, Neimat J, Konrad P, Phibbs F. The factors involved in deep brain stimulation infection: a large case series. Stereotact Funct Neurosurg. 2014;92(4): 227-233.12. Thrane JF, Sunde NA, Bergholt B, Rosendal F. Increasing infection rate in multiple implanted pulse generator changes in movement disorder patients treated with deep brain stimulation. Stereotact Funct Neurosurg. 2014;92(6):360-364.13. Deer TR, Provenzano DA, Hanes M, et al. The Neurostimulation Appropriateness Consensus Committee (NACC) Recommendations for Infection Prevention and Management [published correction appears in Neuromodulation. July 2017;20(5):516]. Neuromodulation. January 2017;20(1):31-50.14. Mekhail NA, Mathews M, Nageeb F, Guirguis M, Mekhail MN, Cheng J. Retrospective review of 707 cases of spinal cord stimulation: indications and complications. Pain Pract. March-April 2011;11(2):148-153.15. Falowski SM, Provenzano DA, XIa Y, Doth AH. Spinal Cord Stimulation Infection Rate and Risk Factors: Results From a United States Payer Database. Neuromodulation. February 2019;22(2):179-189.16. Clifton M, Quirouet A, Pizarro-Berdichevsky J, et al. Infection rate after sacral neuromodulation surgery: a review of 1033 InterStim procedures. J Urol. April 2016;195(4S):851.17. Bjerknes S, Skogseid IM, Sæhle T, Dietrichs E, Toft M. Surgical site infections after deep brain stimulation surgery: frequency, characteristics and management in a 10-year period. PLoS One. August 14, 2014;9(8):e105288.18. Piacentino M, Pilleri M, Luigi Bartolomei L. Hardware-related infections after deep brain stimulation surgery: review of incidence, severity and management in 212 single-center procedures in the first year after implantation. Acta Neurochir (Wien). December 2011; 153(12):2337-2341.19. Hamani C, Lozano AM. Hardware-related complications of deep brain stimulation: a review of the published literature. Stereotact Funct Neurosurg. 2006;84(5-6):248-251.20. Hayek SM, Veizi E, Hanes M. Treatment-Limiting Complications of Percutaneous Spinal Cord Stimulator Implants: A Review of Eight Years of Experience From an Academic Center Database. Neuromodulation. October 2015;18(7):603-608. 21. Bendel MA, O'Brien T, Hoelzer BC, et al. Spinal Cord Stimulator Related Infections: Findings From a Multicenter Retrospective Analysis of 2737 Implants. Neuromodulation. August 2017;20(6):553-557. 22. Wexner SD, Hull T, Edden Y, et al. Infection rates in a large investigational trial of sacral nerve stimulation for fecal incontinence. J Gastrointest Surg. July 2010;14(7):1081-1089.15 23. Chen T, Mirzadeh Z, Lambert M, et al. Cost of Deep Brain Stimulation Infection Resulting in Explantation. Stereotact Funct Neurosurg. 2017;95(2):117-124.24. Provenzano DA, Falowski SM, Xia Y, Doth AH. Spinal Cord Stimulation Infection Rate and Incremental Annual Expenditures: Results From a United States Payer Database. Neuromodulation. April 2019;22(3):302-310.25. Medtronic data on file: Economic Impact of Infection Related to Neuro-Stimulator Implant. Study report prepared for Medtronic prepared by Optum, 2018/01/03.26. Garrigos ZE, Farid S, Bendel MA, Sohail MR. Spinal Cord Stimulator Infection: Approach to Diagnosis, Management, and Prevention. Clin Infect Dis. June 10, 2020;70(12):2727-2735. 27. Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. N Engl J Med. May 16, 2019;380(20):1895-190528. Garrigos ZE, Farid S, Bendel MA, Sohail MR. Spinal Cord Stimulator Infection: Approach to Diagnosis, Management, and Prevention. Clin Infect Dis. June 10, 2020;70(12):2727-273529. Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol. April 2021. doi:10.1001/jamaneurol.2021.0538 Spinal Cord Stimulation Brief Summary INDICATIONS Spinal cord stimulation (SCS) is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs-including unilateral or bilateral pain. CONTRAINDICATIONS Diathermy - Energy from diathermy can be transferred through the implanted system and cause tissue damage resulting in severe injury or death. WARNINGS Sources of electromagnetic interference (e.g., defibrillation, electrocautery, MRI, RF ablation, and therapeutic ultrasound) can interact with the system, resulting in unexpected changes in stimulation, serious patient injury or death. An implanted cardiac device (e.g., pacemaker, defibrillator) may damage a neurostimulator, and electrical pulses from the neurostimulator may cause inappropriate response of the cardiac device. Patients with diabetes may have more frequent and severe complications with surgery. A preoperative assessment is advised for some patients with diabetes to confirm they are appropriate candidates for surgery. PRECAUTIONS Safety and effectiveness has not been established for pediatric use, pregnancy, unborn fetus, or delivery. Avoid activities that put stress on the implanted neurostimulation system components. Recharging a rechargeable neurostimulator may result in skin irritation or redness near the implant site. ADVERSE EVENTS May include: undesirable change in stimulation (uncomfortable, jolting or shocking); hematoma, epidural hemorrhage, paralysis, seroma, infection, erosion, device malfunction or migration, pain at implant site, loss of pain relief, and other surgical risks. Adverse events may result in fluctuations in blood glucose in patients with diabetes. Refer to www. medtronic.com for product manuals for complete indications, contraindications, warnings, precautions and potential adverse events. Rx only. Rev 0422 TYRX™ Neuro Absorbable Antibacterial Envelope Brief Statement The TYRX™ Neuro Absorbable Antibacterial Envelope is intended to hold a vagus nerve stimulator, a spinal cord neuromodulator, a deep brain stimulator or a sacral nerve stimulator securely in order to create a stable environment when implanted in the body. The Neuro Antibacterial Envelope contains the antimicrobial agents Minocycline and Rifampin which, have been shown to reduce infection in an in vivo model of bacterial challenge following surgical implantation of a pulse generator. The Neuro Antibacterial Envelope is NOT indicated for use in patients who have an allergy or history of allergies to tetracyclines, Rifampin, or absorbable sutures. The Neuro Antibacterial Envelope is also NOT indicated for use in patients with contaminated or infected wounds, or Systemic Lupus Erythematosus (SLE). This device is intended to be used in conjunction with vagus nerve stimulators or deep brain stimulators implanted in the infraclavicular fossa, or in conjunction with spinal cord neuromodulators or sacral nerve stimulators implanted laterally to the body midline and slightly superior to the gluteal region. The use of this product in patients with compromised hepatic and renal function, or in the presence of hepatotoxic or renal toxic medications, should be considered carefully, because Minocycline and Rifampin can cause additional stress on the hepatic and renal systems. Patients who receive the Neuro Antibacterial Envelope and who are also taking methoxyflurane should be monitored carefully for signs of renal toxicity. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Dr. Shannon Westin and her guest, Dr. Bryan Schneider discuss the article “ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-induced Peripheral Neuropathy in Black Women with Early Stage Breast Cancer” recently published in the JCO and presented at the 2024 ASCO Annual Meeting. TRANSCRIPT  The guest on this podcast episode has no disclosures to declare. Shannon Westin: Hello, everyone, and welcome to another episode of JCO After Hours, the podcast where we get in depth on manuscripts published in the Journal of Clinical Oncology. I am your host, Shannon Westin, GYN Oncology Extraordinaire and also the Social Media Editor of the Journal of Clinical Oncology. And it is my great pleasure to present some really incredible work today that is going to be a dual publication in the Journal Clinical Oncology and a presentation at the American Society of Clinical Oncology Annual Meeting on Monday, June 3. And this is the “ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-induced Peripheral Neuropathy in Black Women with Early Stage Breast Cancer.” And I am joined today by the senior author on the presentation and the primary author on the manuscript, Dr. Bryan Schneider. He is the Vera Bradley Professor of Oncology, the Professor of Medicine and Medical Molecular Genetics at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis. Welcome, Dr. Schneider. Dr. Bryan Schneider: Dr. Westin, thank you for having me on today. Shannon Westin: We're so excited and we're really excited to really summarize this incredible work that's being presented today. So, first, let's just levelset. Can you speak a little bit about peripheral neuropathy and the most common causes in patients with cancer? Dr. Bryan Schneider: Yeah, I mean, I think for those of us who treat patients using the taxanes, we recognize probably one of the most important and common side effects that we deal with is peripheral neuropathy, and one that can, I think, impact both quality of life, but also impacts the ability to maintain dose intensity. When we think about risk factors for neuropathy, historically, I think obesity has been reported as a potential risk factor, as has diabetes and other conditions which put people at risk for neuropathy. Shannon Westin: And prior to your work that you'll discuss with us today, what do we know about the incidence of peripheral neuropathy in patients that identify as black? Dr. Bryan Schneider: Yeah. So, interestingly, I think we've recognized that patients who self identify as black have disparate outcomes in terms of inferior survival and more aggressive subtypes of breast cancer, like triple negative breast cancer. But I think the idea of toxicity being a disparate factor as well is probably a more recent one. Interestingly, as we set out to identify biomarkers to predict outcomes in the large adjuvant trial E5103, we weren't really setting out to look at this by race. We were using at that time, genome-wide approaches to identify biomarkers for toxicity and also efficacy. But what was interesting as we did that one of the most important predictors, as we looked across a number of important toxicities, was ancestry. And really the science spoke to us, it was very clear that patients of African ancestry had higher rates of bev-induced hypertension, anthracycline-induced cardiomyopathies and also peripheral neuropathy. Shannon Westin: That's so interesting. We have so much overlap in gynecologic oncology and breast cancer. And I don't know that I've ever seen work like this. And now it's making me very intrigued and making me want to move forward to that. Can you talk a little bit more about this ECOG-ACRIN E5103, like briefly about the study and what it demonstrated specifically? Dr. Bryan Schneider: Yeah. So E5103 was an adjuvant breast cancer trial that really set out to look at the impact of bevacizumab in the curative setting. This was a 5000 patient trial that randomized patients the standard backbone of chemotherapy. So everyone received four cycles of doxorubicin and cyclophosphamide, followed by weekly paclitaxel, and then with or without the addition of bevacizumab. So the parent clinical trial showed, as we know now, bevacizumab didn't add benefit, but certainly this was a fertile ground for us to use genomic markers to try to identify a number of other important factors and predictors. Shannon Westin: And what did you find genomically in that study that led to kind of where we are now? Dr. Bryan Schneider: Initially, what we found is that ancestry was a major predictor of neuropathy. And in that trial we saw essentially a doubling of the risk of grade 2 and above and a doubling of the risk of grade 3 and above neuropathy. When we then looked comprehensively across the genome for common variants that might put patients at risk for neuropathy, we had enough patients in the black population to identify some markers that seemed to differentially predict the risk of neuropathy in the patients of African ancestry. So there we found a variant in the gene FCAMR, which appeared to be protected from neuropathy, and FCAMR is known to have an immune modulatory effect. But importantly, we also found that rare variants, so we did this using an exome wide approach in a gene called SPF2, predicted an increased risk of neuropathy. Now, interestingly, that gene SPF2 is also thought to contribute to a hereditary form of neuropathy, Charcot-Marie-Tooth. Here, what we found, obviously, is that if you inherit two of these variants, you probably have a hereditary neuropathy, but if you inherit one, you may not have neuropathy at baseline, but if exposed to a neurotoxin, much more predisposed to that event. Shannon Westin: That is so intriguing and makes so much physiologic sense. So, can you talk a little bit about how that led to the development of the current study, the objectives design, that type of thing? Dr. Bryan Schneider: Yeah. I think, overarching question and concern is, and we see this with all clinical trials in the United States, is that we're seeing disparate outcomes in a population that are largely underrepresented in our clinical trials. And so one of the first things we wanted to do was really focus on the population that was being disparately affected. So EAZ171 was set out to accrue patients, and in fact, only accrue patients who were self described as a Bck race or African American. So the goal of this trial then was to see if, number one, we could further predict which patients were going to get neuropathy based on our germline genotyping, and then also to better personalize the type of taxane based, again on genomics, but also on the risk of dose reductions, risk of neuropathy, impact on financial toxicity, quality of life, and a number of other, what we felt to be, important clinical variables. Shannon Westin: So let's get into the details. What did you find regarding the incidence of neuropathy in the study, and how was it impacted by the type of chemotherapy the patient received? Dr. Bryan Schneider: Yeah. So the starting point, the primary objective of that study, was to try to validate a high and low risk composite score for neuropathy. And the trial was negative, meaning our genotypes did not predict significantly differences based on the germline genotyping. Now, interestingly, the genotyping did numerically separate, meaning those in the high risk category had about a 12% higher risk of neuropathy, but this did not meet statistical significance. Another major or key secondary endpoint, though, was to look at the type of taxane and its impact in this population. And indeed, what we found is that patients who received paclitaxel had a markedly and statistically significantly higher risk of both grade 2 and above and grade 3 and above peripheral neuropathy. And in addition, we saw more dose reductions, both because of TIPN and all causes in the paclitaxel arm. Shannon Westin: So why do you think you were unable to validate the genomic predictors in the current study? Dr. Bryan Schneider: This is an incredibly important question. So, number one, I mean, we were happy to see the directionality of our preliminary data be correct. But I do think that neuropathy is a very complicated toxicity, and it's probably a multigenic effect, and it probably is also impacted a lot by a variety of clinical factors. So some of the future work we'll be doing is looking at polygenic risk scores and other known genes that may be impactful, and also melding that with a number of really important clinical variables, because I still think we have the potential to predict this ahead of time. Shannon Westin: I know that this was such a patient driven topic, really focused on the patient experience and how to improve not only survival outcomes, but also toxicities and quality of life. Can you speak a little bit about the role of patients in the design of this trial, and maybe with helping it be as successful as it was with accrual? Dr. Bryan Schneider: Yeah. This has truly been one of the most exciting projects I've ever embarked on, and largely because of the incredible team atmosphere and contributions by so many people. Real thanks to the late Worta McCaskill-Stevens and also the late Edith Mitchell, who were two really fundamental disparities experts who really helped motor this trial to where it was. And also our patient advocates and the community at large really were part of the design and part of this from the very beginning, all the way through the publication, I think, have made it a clinically relevant study, and one that I think we're all very proud of. Shannon Westin: Is paclitaxel typically, what is the go-to? Or are more people using, let's say, docetaxel? Dr. Bryan Schneider: I think it depends a little bit on the disease setting and type. And again, is a function of historical clinical trials. One of the pivotal trials, E1199, actually compared a number of these. So it compared weekly paclitaxel to every three week paclitaxel to weekly docetaxel to every three week docetaxel in a two by two design. And essentially the conclusion there is that weekly paclitaxel and every three week docetaxel both outperformed what at the time was a standard of care, every three week paclitaxel. Now, weekly paclitaxel, at least through ECOG-ACRIN, has been adopted as kind of the standard reference therapy and schedule of choice, but largely because of the side effect profile. And again, this is based predominantly on white patients, where the tolerability is much better. Shannon Westin: Well, I mean, I think that this leads to really great information around how we're designing these trials and how we're potentially making those differences. What are your next steps here? Dr. Bryan Schneider: So I think one of the things this clinical trial did was first validate that we do see high rates of peripheral neuropathy in Black patients with breast cancer. This was a prospective study using both physician and patient adjudicated variables. So I think this is a really nice validation that this is a problem in this population. I think it also shows us that docetaxel is probably a more tolerable drug for black patients with breast cancer. The goal, though, I think in our future work, is really going to try to bring equity in terms of outcome and side effects. So we're working with ECOG-ACRIN now on our second trial, where really the primary endpoint is going to be to nullify the disparities and try to bring equity in terms of toxicity. One of the other pieces of work we're really excited about is we're doing some ex vivo work. So from patients in EAZ171, we have a blood stick where we're taking white blood cells and differentiating those into peripheral neurons. And here we're hoping to look at really important changes in both gene expression and epigenetics that might lead us to a little bit deeper understanding of the mechanism of the disparities in neuropathy, maybe what's causing some of the neuropathy. And we hope ultimately, these may lead to nice drug targets to help prevent or treat neuropathy down the road. Shannon Westin: Those are some really great ideas. The other thing that really caught my eye around your findings was what you all found regarding the physician reported and patient reported toxicity. I'd love for you to summarize that, because I think that's always a concern as well. Dr. Bryan Schneider: Historically, I think we recognize that physicians probably underreport side effects. And so we felt, and our team felt, that having patient reported outcomes would be a really critical piece to this study. What was fairly astonishing to me, if you look at the CTCAE, both patient and physician reported outcomes, they were actually pretty similar. And I think what this is a testament to is if physicians are actually thinking about the side effect, they do a pretty good job of predicting it. Now, one thing we're looking very forward to is that we have a long term follow up out to three years. So it'll be interesting to see if physicians continue to pay close attention to neuropathy, because I know the patients will be. So we'll be looking at the discordance at these longer term follow up time points as well. Shannon Westin: Well, great. This is such incredible work, and I'm like literally taking notes to get in touch with people I know that do this type of work and gynecological malignancies because I think that this is going to have far reaching consequences. So just thank you so much for taking the time to review this and congratulations on the JCO publication and ASCO presentation. It's very well deserved. Dr. Bryan Schneider: Thank you Dr. Westin. Shannon Westin: And thank you to all of our listeners. Again, we have been discussing the “ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-induced Peripheral Neuropathy in Black Women with Early Stage Breast Cancer.” We're so grateful you joined us, and please do check out our other offerings wherever you get your podcasts. Have an awesome day. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures Research Funding Company name: Genentech/Roche Company name: Pfizer Company name: Foundation Medicine      

In this episode, Carli interviews Scott Schwab, CEO and co-founder of Met Naturals, about the benefits of CBD and hemp. Scott shares his personal journey of using CBD to manage pain and inflammation caused by peripheral neuropathy. He explains how he started Met Naturals to provide high-quality CBD products that are sourced from regenerative farms and undergo rigorous testing. Scott also discusses the differences between hemp and marijuana, the therapeutic properties of CBD, and the extraction methods used by Met Naturals. CBD and other cannabinoids can be used to address various imbalances and symptoms in the body. Common uses include pain management, antioxidant support, sleep improvement, and anxiety relief. CBD can help regulate the circadian rhythm and promote deep, restful sleep. It is important to establish wellness foundations such as hydration, movement, and sunlight exposure. CBD products like gummies and tinctures can be used to manage stress and anxiety, but it is important to start with small doses and find the right amount for each individual. The daily gel caps can provide long-term support for inflammation and overall well-being. It is crucial to listen to the body, establish boundaries, and prioritize self-care. MET Naturals offers a range of CBD products and provides customer support through their website and Instagram.IG: @mett.naturals Website: https://mettnaturals.com/Text Carli your questions or a suggested podcast topic!Carli's Info:Website: www.wellnessbycarli.comIG: @wellnessbycarli

In this podcast, we're going to talk about an amazing natural alternative for peripheral neuropathy. Diabetic neuropathy usually affects the bottom of the feet and sometimes the hands and is one of the first signs of a blood sugar problem. Chemotherapy, hypothyroidism, autoimmune diseases, medications, viruses, and Lyme disease can also lead to peripheral neuropathy. However, high blood sugar and diabetes are the most common causes. Diabetes wears down the myelin sheath over time, leaving exposed nerves at the bottom of the feet. Peripheral neuropathy can feel like hypersensitivity, burning, severe pain, or itching. If it's not corrected, it can lead to ulcers in the lower part of the body and gangrene. Consuming too much sugar makes it difficult for the mitochondria to get enough fuel. Too much sugar also leads to nutrient deficiencies and inhibits the function of enzymes that bring fuel to the cell. When sugar blocks the body's mechanism for getting energy to the cells, it utilizes alternative pathways for energy. One of these alternative pathways produces sorbitol, a sugar alcohol. Sorbitol can damage the lens of the eye, leading to cataracts. It can also affect the retina, leading to diabetic retinopathy. Sorbitol affects the cells that compose the myelin sheath. It can also convert to fructose, creating even more problems. Benfotiamine is a fat-soluble form of vitamin B1 that can help support the nerves. Try taking 300 mg of benfotiamine 4 times daily. Lipoic acid is a cofactor for the enzyme that allows you to metabolize excess glucose. Vitamins B5, B2, and B3 are also cofactors for this enzyme. Diabetes damages your nervous system and brain over time, so it's imperative to correct your diet, which I believe is the root cause of peripheral neuropathy. Learn more about the benefits of a low-carb diet and intermittent fasting in my other videos.

Dr. Devon Rubin challenges the father-son combination of Drs. Peter Dyck and Jim Dyck with a case of peripheral neuropathy. Watch to find out whether the patient's diabetes was the culprit or whether there was another cause. You will not be disappointed as you learn many pearls in the clinical and EDX evaluation of peripheral neuropathy. Visit our website for more information and educational materials ⁠education.aanem.org⁠.

Continuing our discussion with warrior, Kashinda Marche from S2E13. In 1995, Kashinda was a nineteen-year-old, new mother when she received the life-changing diagnosis of HIV. Reaching a breaking point with her mental health, Kashinda chose to focus on changing her mindset. Four neurosurgeries and many diagnoses followed throughout the years including Hidradenitis Suppurative, Autoimmune Disorder, Adrenal Insufficiency, Pituitary Adenoma, and Peripheral Neuropathy. Listen to Part Two as Kashinda shares how discovering of her authentic self fuels her passion to inspire, uplift, and empower African American girls and the chronic illness community as a published author, a certified personal development life coach that specializes in self-esteem strengthening, a TEDx speaker, and an Executive Director of the nonprofit, Kreative On Purpose. Kashinda believes health and life challenges don't need to prevent one from living a fulfilled life. To learn more about Kashinda Marche, her services and her nonprofit, Kreative On Purpose, go to https://www.kreativeonpurpose.org. 

Welcome to the ninth episode of Supportive Care Matters, a podcast Hosted by Medical Oncologist Professor Bogda Koczwara AM from Adelaide, Australia.Navigating the silent struggle that many cancer survivors face, this episode promises insights into the lesser-known yet impactful world of chemotherapy-induced peripheral neuropathy (CIPN). With the expertise of Professor David Goldstein and Associate Professor Susanna Park, this episode sheds light on how CIPN disrupts daily life in ways that go unnoticed by the medical community.From the nuanced challenges of assessing the severity of this condition to the cognitive toll it takes on patients, Bogda leads a discussion on the critical need for sensitive and precise management strategies that can truly make a difference.The conversation takes a deep look into the tools and techniques that are transforming how we understand and measure CIPN. Our guests articulate the importance of patient-reported experiences in guiding interventions and the potential benefits of exercise in mitigating neuropathic symptoms. Through this dialogue, we recognise the dedication and collaborative efforts that are pushing the envelope in neuropathy research and care, offering a glimmer of hope for those battling with the long-lasting effects of their cancer treatments.This episode stands as a testament to the resilience of the human spirit and the ongoing efforts to provide supportive care that truly matters. Subscribe and like to join our mission of bringing these crucial conversations to the forefront and make supportive care matter.This conversation is produced by The Oncology Network.TO VIEW SHOW NOTES AND MORE INFORMATION ABOUT SUPPORTIVE CARE MATTERS, HEAD TO WWW.ONCOLOGYNEWS.COM.AU

We are throwing back to S2E12 with warrior, Kashinda Marche. In 1995, Kashinda was a nineteen-year-old, new mother when she received the life-changing diagnosis of HIV. Reaching a breaking point with her mental health, Kashinda chose to focus on changing her mindset. Four neurosurgeries and many diagnoses followed throughout the years including Hidradenitis Suppurative, Autoimmune Disorder, Adrenal Insufficiency, Pituitary Adenoma, and Peripheral Neuropathy. Tune in to Part One as we hear Kashinda tell her remarkable story and explain the importance of mindset and of discovering her authentic self. This discovery fuels her passion to inspire, uplift, and empower African American girls and the chronic illness community as a published author, a certified personal development life coach that specializes in self-esteem strengthening, a TEDx speaker, and an Executive Director of the nonprofit, Kreative On Purpose. Kashinda believes health and life challenges don't need to prevent one from living a fulfilled life. To learn more about Kashinda Marche, her services and her nonprofit, Kreative On Purpose, go to https://www.kreativeonpurpose.org. 

Have you ever felt a mysterious tingling or numbness in your hands and feet, but couldn't pinpoint the cause? You're not alone, and the culprit might be an unexpected source: celiac disease. On our latest episode, we uncover the hidden connection between peripheral neuropathy and celiac disease, discussing why it's crucial for the to recognize these symptoms. By committing to a strict gluten-free diet, those suffering from this chronic pain can embark on a journey to reclaim their comfort and well-being.But there's more—celiac disease can bring along a companion in the form of diabetes, with symptoms that extend far beyond the gut. I talk you through the tightness, swelling, and burning that many with celiac disease might mistake for something less sinister. This episode is not just about identifying these red flags but also about taking action through regular diabetes screenings and embracing a gluten-free lifestyle. Learn more about Ultimate Celiac System herewww.belindawhelan.com/ultimateceliacsystemJoin my free community and grab your copy of 11 Mistakes People Make Living Gluten Free here www.belindawhelan.myflodesk.com/11mistakesCheck out my Daily Health Tracker hereHEALTH TRACKER | The Healthy Celiac (belindawhelan.com)And I would love to connect with you on Instagram thehealthyceliacIf you have a spare moment, please pop over to Apple Podcasts and leave me a review. Let me know what you like, what you've taken on board and what you'd like to hear more of. Thank you!Music Credit bensound.com 

In a recent review of randomized controlled trials, scientists found exercise to be a powerful tool for the treatment and prevention of peripheral neuropathy.A big source of hope for these patients, for symptom management & prevention.

What is Peripheral Neuropathy? Tuesday on Mornings with Eric and Brigitte, Dr. Mike Rozenblum, chiropractor at Genesis Physical Medicine and Chiropractic in Fort Lauderdale joins us to discuss Peripheral Neuropathy, a condition that happens when the nerves that are located outside of the brain and spinal cord (peripheral nerves) are damaged. Dr. Rozenblum will address the causes and some of the symptoms of this condition.See omnystudio.com/listener for privacy information.

In this informative episode, learn which VA rating you may be eligible for if you are suffering from peripheral neuropathy. Veterans may receive service connection for peripheral neuropathy on a direct basis, by secondary service connection, or through presumptive service connection. It's important to note that VA does not have a specific code for peripheral neuropathy and is often based on which nerves are involved. Tune in to learn more! Follow us on social media: ⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠ - ⁠⁠⁠⁠⁠⁠https://bit.ly/CCKYTL⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠ - ⁠⁠⁠⁠⁠⁠https://bit.ly/CCKFBL⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠ - ⁠⁠⁠⁠⁠⁠https://bit.ly/CCKINL⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠ - ⁠⁠⁠⁠⁠⁠https://bit.ly/CCKTL

Now more than ever, we need to advocate for our own health and self-care. Similarly, we need to look out for those closest to us and prepare ourselves for when we might need to step up and support them, be it an aging parent or a friend who's been diagnosed with a chronic health condition.  Our guest today is Keith Day, a medical consultant, also known as the Neuropathy Warrior. A dedicated thought leader and founder of Neuropathy Truth, Keith has over two decades of personal experience battling peripheral neuropathy. His unique blend of first-hand experience and expert knowledge has made him a beacon of hope for others struggling with similar conditions.  Listening in, you'll hear Keith's thoughts on living with peripheral neuropathy, how he put his neuropathy into remission, what we can do to support anyone struggling with this condition, and much more. To hear this insightful conversation with a resilient advocate, be sure to tune in!What you'll learn about in this episode:A breakdown of the different types of neuropathy.The symptoms of neuropathy and the diseases that can cause it.Unpacking the differences between acute and chronic inflammation.How Keith treats his clients and how he helps them put their neuropathy into remission.An overview of the five stages of neuropathy.Keith's approach to pharmaceuticals and treating the cause of neuropathy.How to increase blood flow and decrease inflammation.The key role of nitric oxide and how to increase it through your diet.Advice on how to do mild exercise when you have neuropathy.Keith's insights on Type 2 diabetes and its relationship to neuropathy.How Keith educates his patients and what you can expect if you reach out to him.Advice on what to be aware of when looking for healthcare providers and treatment.The protocol that helps neuropathy patients go off medication.Transcript: HereAdditional Resources:Website: https://neuropathywarrior.com/LinkedIn: https://www.linkedin.com/in/keith-day-4bbb21143/Phone Number: 205-206-7542Links Mentioned:Peripheral Neuropathy | National Institute of Neurological Disorders and StrokeSuperBeetsSharon Spano:Website: sharonspano.comFacebook: facebook.com/SharonSpanoPHDInstagram: instagram.com/drsharonspano/LinkedIn: linkedin.com/in/sharonspano/Book: thetimemoneybook.comContact: sharon@sharonspano.comX: twitter.com/SharonSpanoThe Other Side of Potential Podcast: sharonspano.com/podcast/

“I think educating patients of what can happen and those are the symptoms you're really looking for to decrease this from getting to the severe level is like the sensory stuff. It's kind of your starting point and it progresses from there,” Colleen Erb, MSN, CRNP, ACNP-BC, AOCNP®, hematology and oncology nurse practitioner at Jefferson Health Asplundh Cancer Pavilion in Willow Grove, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about what nurses need to know about cancer- and treatment-related peripheral neuropathy. This episode is part of a series on cancer symptom management basics; the rest are linked below.  You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD), which may be applied to the symptom management, palliative care, and supportive care ILNA categories, by listening to the full recording and completing an evaluation at myoutcomes.ons.org by December 15, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: The learner will report an increase in knowledge related to peripheral neuropathy.  Episode Notes  Complete this evaluation for free NCPD.   Oncology Nursing Podcast Cancer Symptom Management Basics series  Clinical Journal of Oncology Nursing articles: Balance and Gait Impairment: Sensor-Based Assessment for Patients With Peripheral Neuropathy  Chemotherapy-Induced Peripheral Neuropathy: Use of an Electronic Care Planning System to Improve Adherence to Recommended Assessment and Management Practices Instruments for Assessing Chemotherapy-Induced Peripheral Neuropathy: A Review of the Literature Extremity Cooling: A Synthesis of Cryotherapy Interventions to Reduce Peripheral Neuropathy and Nail Changes From Taxane-Based Chemotherapy  Oncology Nursing Forum article: Chemotherapy-Induced Peripheral Neuropathy Assessment Tools: A Systematic Review  ONS Symptom Interventions and Guidelines™: Peripheral Neuropathy  American Cancer Society's patient information for peripheral neuropathy  American Society of Clinical Oncology (ASCO) Guideline: Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers  Multinational Association of Supportive Care in Cancer (MASCC): Neurological Complications  Overview of nursing skills for routine neurologic assessments   To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From Today's Episode  “Our nervous system is sort of divided into three parts. The autonomic nervous system, which is kind of controlled homeostasis, blood pressure, your intestinal motility, things like that. The motor system, which is the efferent system, which is reflexes, muscle strength, sort of your big muscle movements, if you want to think of it that way. And then the sensory system, which is the afferent system, which is really what defines motion.” TS 1:51  “I think patients tend to blow off the mild numbness and tingling because they're just like, ‘Oh, it's just the side effect of my chemo' and they don't realize that that can get progressively worse. So, they tend to not tell you, you know, ‘Oh do you have numbness and tingling? Yeah, I get it every visit.' But they're like, ‘No, no, it's fine. It's just once in a while,' and all of a sudden, two months down the line, they come in and they can't walk as well.” TS 6:53  “Some other disease-related comorbidities, things like diabetes, thyroid disease, there's nutritional deficiencies—like vitamin B is a big one. We tend to check B12, but B1, which is thiamin, can also cause this. Other things like inherited neurologic disease, toxin exposures like alcohol and people with alcohol dependance, infections like HIV and herpes or shingles as we all know it. Cardiac disease, which, you know, peripheral vascular particularly, but other cardiac diseases can do it too. And then medications that people have been on forever, you know, there's a list of like the highly likely ones, things like amiodarone, aminoglycosides, colchicine, hydralazine, metronidazole, linezolid, and statins can actually cause a preexisting peripheral neuropathy or make you more likely to develop it in the duration of your cancer treatment.” TS 9:38  “I think the most important thing for any patient, but specifically when you're looking for peripheral neuropathy is a really good history and review of systems like other medications, any supplements, any comorbidities, any underlying diseases that they may not be treated for yet, or things like that. But a good history can really go a long way in finding out sort of your risk factors.” TS 11:55  “I think nurses knowing how to do a basic neuro exam, you know, we all learn this. But do we actually do it all the time? Probably not. But I think really knowing how to like, you know, can they feel a light touch or a pinprick, test their muscle strength, watch them walk down the hallway and see if it changes over time? Like are they starting to sway a little bit when they walk? Can they get out of the chair without pushing on the handle and using their arms to get up? Things like that really can tell you a lot.” TS 13:36  “Sadly, there's really nothing proven to prevent the development of neuropathy. You know, we know that you can't really catch it before people start having symptoms. Unfortunately, it's really when you start to detect symptoms that you can prevent it from getting to the severe point where it's really impacting their quality of life. And I think the biggest thing is proactive assessment and diagnosing it when it's early and being able to kind of intervene before it gets to the point of debilitating.” TS 16:52  “It can really happen to anyone at any time. And generally, with any drug, not just those ones that it's the tough side effect; it really can affect any drugs. So, assessment is kind of key for everyone.” TS 27:06 

Uncontrolled high blood sugar damages nerves and interferes with their ability to send signals, leading to diabetic neuropathy. High blood sugar also weakens the walls of the small blood vessels (capillaries) that supply the nerves with oxygen and nutrients. High blood glucose levels and high levels of fats, such as triglycerides, cholesterol can damage nerves. Different types of nerve damage cause different symptoms. Symptoms can range from pain and numbness in your upper & lower limbs & it may also affect the functions of internal organs, such as heart and urinary bladder, sex organ etc. The most common symptoms of diabetic neuropathy are numbness, tingling, a burning feet, aching, cramps and weakness. There are different types of neuropathy, the Peripheral Neuropathy (very common and typically affects feet and legs), autonomic neuropathy (causes damage to nerves that control internal organs, leading to problems with heart and blood pressure, digestive system, urinary bladder, sex organs, sweat glands, and eyes. ). Peripheral neuropathy can be detected with the filament test or biothesiometer. Cardiac autonomic neuropathy requires multiple tests through Cardiologist. Keeping your blood sugar, cholesterol & blood pressure within a healthy range and avoiding alcohol & smoking is the best way to decrease the developing of diabetic neuropathy. Broadcasted on 27.10.2023

In this episode of the Straight A Nursing podcast, we're breaking down the key things a nurse needs to know about peripheral neuropathy. This is a condition in which the distal nerves of the hands and feet are damaged and unable to transmit messages correctly. The result is numbness, tingling, weakness and pain (often quite severe pain!). In this episode you'll learn:  The many different causes of peripheral neuropathy and which one is most common Complications of the condition Signs and symptoms of peripheral neuropathy Important nursing assessments Tests utilized to diagnose or evaluate peripheral neuropathy Treatments including pharmacological and non-pharmacological therapies Key elements to include in your education plan __________ Full Transcript - Read the article and view references. FREE CLASS - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! Nursing School Thrive Guide - Get the book that many nursing students consider the ultimate survival guide for nursing school! Available in paperback, Kindle and audio formats. Pharmacology Success Pack - Want to get a head start on pharmacology? Download the FREE Pharmacology Success Pack. LATTE Method Template - Download the free LATTE Method Template so you can streamline how you study and focus on what a nurse needs to know.

For more information, visit https://thecirsgroup.com It's that time again! Barbara and Jacie take your CIRS questions live! CIRS, or Chronic Inflammatory Response Syndrome, is a multi-symptom, multi-system illness that can wreck havoc on your health. Today we are doing a live Q&A to let people ask us their most pressing questions about CIRS, CIRS treatment, management of symptoms, and anything moldy. We cover diet, brain scans, MCAS, POTS, GAPS, emotional trauma, Lyme, and more! To join our online support community, visit TheCIRSGroup.com TIME STAMPS: 0:52 Welcome to The CIRS Group Fall 2023 Webinar 1:25 What is The CIRS Group? 2:50 Why air samples are not sufficient for CIRS patients 4:40 Best way to time taking supplements and binders 7:00 When to take the VCS test 9:10 Treating Lyme or other exposures with CIRS treatment 11:15 Elhers Danlos Syndrome 12:00 MCAS or Mast Cell Activation Syndrome 15:33 NueroQuant and memory loss 18:22 How long it took Jacie and Barbara to feel better 21:53 Peripheral Neuropathy - why it happens and tips for management 24:30 Thyroid medications and binder timing 25:02 Cromolyn Sodium for MCAS 25:54 How to get a NeuroQuant MRI 27:05 International TCG members and resources 28:00 How to order a NeuroQuant 28:36 Psyllium husk vs okra and beet binders 29:35 What can you do now while waiting to start treatment 32:15 Taking okra or beet supplements in the meantime 33:17 POTS: Postural orthostatic tachycardia syndrome 34:37 Carbs and their potential role in managing CIRS 36:30 GAPS diet 37:38 Breaking the cycle: Pushing and Crashing 41:27 Benefits of processing emotional trauma 44:47 Advice managing co-infections and autoimmune 47:00 Working with Nutrition with Judy 51:38 Oxalate concerns 52:35 Concerns around colonoscopies LINKS Surviving Mold Indoor Environment Testing https://www.survivingmold.com/docs/Inside_Indoor_Air_Quality.PDF NeuroQuant info at Survivingmold.com: https://www.survivingmold.com/resources-for-patients/diagnosis/neuroquant International practitioners and resources: https://www.survivingmold.com/shoemaker-protocol/international-practitioners Work with Nutrition with Judy: https://www.nutritionwithjudy.com/   Jacie is a 4 year carnivore, certified nutrition coach, and carnivore recipe developer determined to share the life changing information of carnivore and CIRS to anyone who will listen. Barbara is a coach, facilitator, speaker, 3 year carnivore, and a big fan of health and freedom. Together, they co-founded The CIRS Group, an online support community to help people that are struggling with their CIRS diagnosis and treatment. Catch Jacie and Barbara on Judy Cho's podcast to learn more about their health journeys and why they started The CIRS Group: When Carnivores are Affected by Mold Illness - Jacie Gregory & Barbara Williams - https://youtu.be/CR8Uj-d_fok

Hey podcast community, Dr. Mark here. My team and I are so excited to offer you a 7 Day Free trial of the Dr. Hyman+ subscription for Apple Podcast. For 7 days, you get access to all this and more entirely for free! It's so easy to sign up. Just go click the Try Free button on the Doctor's Farmacy Podcast page in Apple Podcast. In this teaser episode, you'll hear a preview of our monthly Ask A Doctor Anything episode with Dr. Elizabeth Boham.Want to hear the full episode? Subscribe now. With your 7 day free trial to Apple Podcast, you'll gain access to audio versions of:- Ad-Free Doctor's Farmacy Podcast episodes- Exclusive monthly Functional Medicine Deep Dives- Monthly Ask Mark Anything Episodes - Bonus audio content exclusive to Dr. Hyman+Trying to decide if the Dr. Hyman+ subscription for Apple Podcast is right for you? Email my team at plus@drhyman.com with any questions you have. Please note, Dr. Hyman+ subscription for Apple Podcast does not include access to the Dr. Hyman+ site and only includes Dr. Hyman+ in audio content. Hosted on Acast. See acast.com/privacy for more information.

We were delighted to welcome Matthew Bauer on the podcast to discuss the evidence base of acupuncture for peripheral neuropathy. Also don't miss Matthew's summary of the most important research ever done on acupuncture!Matthew Bauer became interested in Chinese Medicine after becoming a student of a 74th generation Taoist Master and traditional Chinese Doctor in 1978. He became licensed as an Acupuncturist in 1986 and opened his Chinese Medicine practice in California that same year. Matthew developed a passion for educating people about the benefits of acupuncture and became active in acupuncture/Chinese medicine organizations thinking those organizations would have public outreach as a primary goal. When that proved not to be the case, Matthew authored a book for the public exploring the roots and practice of acupuncture titled “The Healing Power of Acupressure and Acupuncture”. He later authored another book for acupuncturists on practice building titled “Making Acupuncture Pay”. In 2014, while still in full time practice seeing around 20 patients a day, Matthew formed the Acupuncture Now Foundation (the ANF) – a for the public benefit charitable organization with the goal of educating the public, healthcare providers, and health policymakers about the practice of acupuncture. Matthew feels the ANF vision statement sums up his goals best – “Creating a world where the benefits of acupuncture are known and available to all.” As part of that vision, Matthew became interested in acupuncture research especially the potential for false negatives due to studies using sub-optimal treatment dosages. Matthew has a particular interest in acupuncture dosage and recently co-authored a journal article on the subject “Is Acupuncture Dose Dependent - Ramifications of acupuncture treatment dose within clinical practice and trials”.Get in TouchLearn Matthew's Peripheral Neuropathy ProtocolLonghurst research on acupuncture for blood pressure

In this interview for Breast Cancer Awareness Month, Dr. Connie Visovsky, Professor and Endowed Chair in Nursing Science at the University of South Florida, shares her research regarding exercise as a self-management strategy for chemotherapy-induced peripheral neuropathy (CIPN) experienced by patients during breast cancer treatment. Additionally, she gives an update on her presentation from last year's ODACon Breast Cancer Symposium regarding new directions in research for CDK4/6 inhibitors.

In the second episode, Solomon Tesfaye and Ollie Binns-Hall unravel the intricate relationship between diabetes and pain. They focus on the current approaches to identifying diabetic peripheral neuropathy and explore the risk factors, and current detection and management approaches, identifying the challenges associated with managing this multifaceted condition.   This content has been supported by Viatris

You've heard me talk on here several times about the impact that sugar has on our health and I have an expert on the show today that is going to drive this concept even further home plus a lot more! Dr. Richard Jacoby is the author of Sugar Crush and has an upcoming book called, "Unglued". Dr. Jacoby is a world renowned foot and ankle surgeon and the Director of Vally Foot Surgeons.  We discuss hidden sugars, some current event topics you may agree or disagree with, and much more!   Time Stamps:   (0:40) Dr. Richard Jacoby's Bio (3:48) What is Peripheral Neuropathy? (12:38) Reading Labels (23:12) The Love Bug Audience (33:48) The Podcasting Industry (49:00) NFL Example (54:48) Connecting with Dr. Jacoby -------------------- Sugar Crush on Amazon: https://a.co/d/7jhAvxH Preorder Unglued: https://www.un-glued.com/book-un-glued Website: www.extremityhealthcenters.com Instagram - www.instagram.com/dr.richardjacoby -------------------- Check Out My New Book Finding Purpose in the Pause -------------------- Eros Body Composition scale: Use Code: Covino for a 20% off discount http://www.inevifit.com?aff=325 -------------------- Thorne Supplements: https://www.thorne.com/u/Covino -------------------- Check Out My YouTube Channel -------------------- Follow me on Instagram! - https://www.instagram.com/carolcovinofitness/

In the newest episode of AbbottTalks, Allen Burton, Divisional VP and Chief Medical Officer of Neuromodulation at Abbott, shares insights into the company's innovative neuromodulation therapies. Burton delves into Abbott's FDA-approved treatment for chronic back pain, which uses electrical stimulation to alleviate pain, improve functionality, and reduce reliance on opioids. Burton discusses Abbott's recent FDA approval to treat people who suffer from back pain with limited surgical options. He also expands on how the company's pioneering treatment for painful diabetic peripheral neuropathy, a condition affecting millions of Americans. This treatment uses electrical stimulation to dampen painful signals in the feet, enabling patients to regain mobility and control over their lives. Burton further introduces the Eterna SCS System, the smallest neurostimulation system in the market, which offers patients a low charging burden and indications for MRI compatibility. Listen to the full episode to hear directly from Abbott's Neuromodulation CMO on how Abbott's patient-centric neuromodulation therapies are impacting the lives of patients suffering from chronic pain and diabetic peripheral neuropathy. Thank you to Resonant Link for sponsoring this episode of AbbottTalks. For more information about Resonant Link go to www.Resonant-Link.com. Thank you for listening to the AbbottTalks Podcast.

Hosts: Carolyn McMakin, MA, DC Kim Pittis, LCSP, (PHYS), MT 2:36 - Busy summer 5:17 Peripheral Neuropathy 11:42 "The hippocampus gets paid to remember every bad thing that ever happened" 16:37 "13 loves to be mobilized" Reboot 22:16 Talking about pain ...

Living The Full Life with Dr. Juan from Saturday, July 8TH, 2023

Peripheral neuropathy afflicts millions of diabetes patients around the world, causing sensations from tingling to pain to complete numbness. For our season finale, we discussed peripheral neuropathy with bioengineer Christian Metallo, whose recent research has uncovered how insulin-regulated metabolism of lipids and amino acids contributes to peripheral neuropathy. Dr. Metallo spoke with us about the inspiration for this research and explained his team's key findings about the links between insulin, the amino acids serine and glycine, and peripheral neuropathy in diabetes patients.

At the 2023 American Society of Clinical Oncology Annual Meeting Dr. Marisa Weiss, founder and chief medical officer of Breastcancer.org, presented results from her study looking at cannabis to ease peripheral neuropathy caused by chemotherapy. Listen to the podcast to hear Dr. Weiss explain: how chemotherapy causes peripheral neuropathy the cannabis product she studied and how it can be obtained what the results mean for people with peripheral neuropathy

Several medication classes can be used to treat diabetic peripheral neuropathic pain (DPNP); however, many patients have a suboptimal response or experience dose-limiting side effects. Treatment guidelines suggest several first-line options but, in the absence of compelling evidence, offer no direction as to which agent to try first or if we should consider combination therapy. Guest Authors: Shilpa Klocke, PharmD, BCPS and Nicole Hahn, PharmD, BCACP Music by Good Talk

Continuing our discussion with warrior, Kashinda Marche. In 1995, Kashinda was a nineteen-year-old, new mother when she received the life-changing diagnosis of HIV. Reaching a breaking point with her mental health, Kashinda choose to focus on changing her mindset. Four neurosurgeries and many diagnoses followed throughout the years including Hidradenitis Suppurative, Autoimmune Disorder, Adrenal Insufficiency, Pituitary Adenoma, and Peripheral Neuropathy. Listen to Part Two as Kashinda shares how discovering of her authentic self fuels her passion to inspire, uplift, and empower African American girls and the chronic illness community as a published author, a life lesson speaker, a TEDx speaker, an Executive Committee Member with The Raleigh-Apex NC NAACP and an Executive Director of the nonprofit, Kreative On Purpose. Kashinda believes health and life challenges don't need to prevent one from living a fulfilled life. To learn more about Kashinda Marche, her services and her nonprofit, Kreative On Purpose, go to https://www.kreativeonpurpose.org.

Meet warrior, Kashinda Marche. In 1995, Kashinda was a nineteen-year-old, new mother when she received the life-changing diagnosis of HIV. Reaching a breaking point with her mental health, Kashinda choose to focus on changing her mindset. Four neurosurgeries and many diagnoses followed throughout the years including Hidradenitis Suppurative, Autoimmune Disorder, Adrenal Insufficiency, Pituitary Adenoma, and Peripheral Neuropathy. Tune in to Part One as we hear Kashinda tell her remarkable story and explain the importance of mindset and of discovering her authentic self. This discovery fuels her passion to inspire, uplift, and empower African American girls and the chronic illness community as a published author, a life lesson speaker, a TEDx speaker, an Executive Committee Member with The Raleigh-Apex NC NAACP and an Executive Director of the nonprofit, Kreative On Purpose. Kashinda believes health and life challenges don't need to prevent one from living a fulfilled life. To learn more about Kashinda Marche, her services and her nonprofit, Kreative On Purpose, go to https://www.kreativeonpurpose.org.

#netflix #socialdilemma #neurofeedback #neurofeedbackpodcast #mentalhealth Jay Gunkelman the man who has read over 500,000 brain scans and Pete Jansons discuss Netflix's Documentary "The Social Dilemma" on The NeuroNoodle Neurofeedback Podcast. Topics include: Free Will, Political Advertising, Internet Addiction, "snip the puppet wires", positive intermittent reinforcement, manipulation, Neurofeedback and Obsessive Compulsive Disorder OCD, Clowns Feet, TMS, Mood Regulatory Patterns, Peripheral Neuropathy, Multiple Sclerosis, Anterior Cingulate, Bipolar, Rapid Cycling, Limbic System, Hypnosis, Social Media and its affect on pre teens, amygdala, Frontal Lobe EEG, Dopamine, Depression, Negativity Bias, Positivity Bias, Slot Machine Turn off your Notifications --- Send in a voice message: https://anchor.fm/neuronoodle/message Support this podcast: https://anchor.fm/neuronoodle/support